WEBULL
News
FATE
1.050
-2.68%
-0.030
Weekly Report: what happened at FATE last week (1208-1212)?
Weekly Report · 4d ago
Fate Therapeutics (FATE) Gets a Buy from Wedbush
TipRanks · 12/09 13:36
Fate Therapeutics presents updated Phase 1 data of FT819
TipRanks · 12/08 13:21
Fate Therapeutics Presents Updated Clinical Data From Its Ongoing Phase 1 Trial Evaluating Its Ft819 Off-The-Shelf iPSC-derived Car T-cell Program In Systemic Lupus Erythematosus And Unveiled New Preclinical Data From Next-Gen. Off-The-Shelf iPSC-Derived Car T-cell Programs For Hematologic Malignancies And Autoimmune Diseases At 2025 American Society Of Hematology Annual Meeting
Benzinga · 12/08 13:12
Fate Therapeutics Reports Promising Phase 1 Results for Off-the-Shelf CAR T-Cell Therapy in Lupus
Reuters · 12/08 13:00
Weekly Report: what happened at FATE last week (1201-1205)?
Weekly Report · 12/08 10:27
Weekly Report: what happened at FATE last week (1124-1128)?
Weekly Report · 12/01 10:22
Fate Therapeutics to Present at Piper Sandler Annual Healthcare Conference
Reuters · 11/25 13:00
Weekly Report: what happened at FATE last week (1117-1121)?
Weekly Report · 11/24 10:27
Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts
TipRanks · 11/18 03:55
Weekly Report: what happened at FATE last week (1110-1114)?
Weekly Report · 11/17 10:28
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
TipRanks · 11/17 07:30
Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks
TipRanks · 11/16 06:00
Fate Therapeutics (FATE) Receives a Hold from Bank of America Securities
TipRanks · 11/15 17:35
Analysts Have Conflicting Sentiments on These Healthcare Companies: Indaptus Therapeutics (INDP) and Fate Therapeutics (FATE)
TipRanks · 11/13 19:40
Fate Therapeutics: Balancing Potential and Uncertainty with FT819’s Promise in Autoimmune Treatment
TipRanks · 11/13 15:25
Fate Therapeutics GAAP EPS of -$0.27 beats by $0.01, revenue of $1.74M beats by $0.06M
Seeking Alpha · 11/13 14:34
Fate Therapeutics Q3 EPS $(0.27) Beats $(0.29) Estimate, Sales $1.741M Beat $1.535M Estimate
Benzinga · 11/13 13:41
Fate Therapeutics Q3 net loss widens
Reuters · 11/13 13:38
*Fate Therapeutics 3Q Rev $1.7M >FATE
Dow Jones · 11/13 13:31
More
Webull provides a variety of real-time FATE stock news. You can receive the latest news about Fate Therapeutic through multiple platforms. This information may help you make smarter investment decisions.
About FATE
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.